F
Fangyi Zhao
Researcher at Eli Lilly and Company
Publications - 7
Citations - 383
Fangyi Zhao is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Ixekizumab & Autoinjector. The author has an hindex of 6, co-authored 7 publications receiving 265 citations.
Papers
More filters
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados,James Cheng-Chung Wei,Robert Landewé,Joachim Sieper,Xenofon Baraliakos,Filip Van den Bosch,Walter P. Maksymowych,Joerg Ermann,Jessica A. Walsh,Tetsuya Tomita,Atul Deodhar,Désirée van der Heijde,Xiaoqi Li,Fangyi Zhao,Clinton C. Bertram,Gaia Gallo,Hilde Carlier,Lianne S. Gensler +17 more
TL;DR: Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks.
Journal ArticleDOI
Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A)
K. Callis Duffin,Jerry Bagel,M. Bukhalo,I.J. Mercado Clement,S.L. Choi,Fangyi Zhao,Anne M. Gill,Beth A. Pangallo,Catherine L Shuler,Lotus Mallbris,K. Jackson +10 more
TL;DR: The efficacy of ixekizumab, an anti‐interleukin‐17A (anti‐IL‐ 17A) monoclonal IgG4 antibody, was demonstrated in moderate‐to‐severe psoriasis patients when administered via prefilled syringe (PFS).
Journal ArticleDOI
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study
Josef S Smolen,Michael E. Weinblatt,Désirée van der Heijde,William F. C. Rigby,Ronald F van Vollenhoven,Clifton O. Bingham,Melissa Veenhuizen,Anne M. Gill,Fangyi Zhao,Wendy J. Komocsar,Pierre Yves Berclaz,R Ortmann,Chin Lee +12 more
TL;DR: Neither clinical efficacy nor significant safety signals were observed with tabalumab despite evidence of biological activity and this study was terminated early due to insufficient efficacy.
Journal ArticleDOI
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.
Kristina Callis Duffin,Michael Bukhalo,Margaret A Bobonich,David Shrom,Fangyi Zhao,James R. Kershner,Anne M. Gill,Beth A. Pangallo,Catherine L Shuler,Jerry Bagel +9 more
TL;DR: Subjects using the autoinjector in a clinical trial felt it was easy to use and felt confident while using it, and the ixekizumab autoin injector was used successfully by patients and caregivers with or without training.